Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative Study

Diana G. Dills; Jill Schneider; null The Glimepiride/Glyburide Research Group

doi:10.1055/s-2007-979831

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 1996; 28(9): 426-429
DOI: 10.1055/s-2007-979831

Clinical

Clinical Evaluation of Glimepiride versus Glyburide in NIDDM in a Double-Blind Comparative Study

Diana G. Dills¹ , Jill Schneider² , The Glimepiride/Glyburide Research Group

¹Department of Medicine, Section of Endocrinology, University of Wisconsin, Madison, Wisconsin, U.S.A.
²Hoechst Marion Roussel Pharmaceuticals Inc., Clinical Research, Bridgewater, New Jersey, U.S.A.

Abstract

PDF Download

Abstract

We report on the results of a one-year, multicenter, randomized, double-blind, parallel-group titration study of the new sulfonylurea agent, glimepiride, versus use of non-micronized glyburide to treat 577 patients with non-insulin dependent diabetes mellitus (NIDDM). Similar decreases in both fasting plasma glucose and HbA1C were found using glimepiride and glyburide. There was a lower incidence of hypoglycemia with glimepiride than glyburide.

Key words

Glimepiride - Glyburide - Non-Insulin Dependent Diabetes Mellitus - Sulfonylurea - Double-Blind Study

PDF (325 kb)